Behavioral
DLP Frye Regional Medical Center LLC
DLP Frye Regional Medical Center LLC was paid $8.84M by Medicaid between Jan 2018 and Dec 2024, across 79 billing codes. Its largest line is 99284, emergency room visit (serious) — 32% of everything it billed.
33Billing provider infoDLP FRYE REGIONAL MEDICAL CENTER LLC
HICKORY, NC 28601
HICKORY, NC 28601
33aNPI1801823349assigned 06/28/2006
33bProvider typeClinical Psychologist
28Total paid$8.84M
24GClaims141,619
24DCodes billed79
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Psychologist providers in North Carolina
Rank by total paid#2 of 58
Median peer was paid$52K
This provider vs. median170×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,236 | $801K | |
| 2019 | 23,070 | $906K | |
| 2020 | 14,169 | $757K | |
| 2021 | 19,344 | $1.25M | |
| 2022 | 22,009 | $1.79M | |
| 2023 | 24,711 | $1.84M | |
| 2024incomplete | 21,080 | $1.51M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 32% | 16,208 | 13,589 | $2.87M |
| 41899 | Unlisted procedure, dentoalveolar structures | 26% | 2,020 | 1,777 | $2.26M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 18,486 | 15,813 | $1.86M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.4% | 1,732 | 1,438 | $387K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.3% | 1,891 | 1,603 | $202K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.5% | 6,304 | 5,557 | $134K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 18,209 | 15,032 | $113K |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 2,112 | 1,776 | $113K |
| 80053 | Comprehensive metabolic panel | 1.2% | 14,314 | 11,965 | $102K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 1,452 | 1,194 | $101K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.1% | 3,793 | 3,157 | $95K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,578 | 2,012 | $73K |
67 more codes
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 336 | $52K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 949 | $35K |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,044 | $34K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,923 | $34K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,635 | $32K |
| 81001 | <1% | 10,369 | $28K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 645 | $27K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,024 | $23K |
| 87631 | <1% | 371 | $23K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,028 | $20K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,096 | $16K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 467 | $15K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,518 | $14K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,927 | $14K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 450 | $13K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 44 | $13K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 354 | $11K |
| 87581 | <1% | 390 | $10K | |
| 87486 | <1% | 390 | $10K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 416 | $9K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,726 | $9K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 13 | $7K |
| 84484 | <1% | 758 | $5K | |
| 87400 | <1% | 142 | $4K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 59 | $4K |
| 71045 | Radiologic examination, chest; single view | <1% | 151 | $4K |
| 83690 | <1% | 714 | $4K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 309 | $4K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 227 | $4K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 504 | $4K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 930 | $4K |
| 93296 | <1% | 543 | $3K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 13 | $3K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 36 | $3K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 35 | $3K |
| 62323 | <1% | 14 | $2K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 50 | $2K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 304 | $2K |
| 81025 | <1% | 262 | $2K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 342 | $2K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 34 | $2K |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 149 | $2K |
| 87150 | <1% | 43 | $2K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 155 | $1K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 43 | $1K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 30 | $1K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 193 | $946.22 |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 28 | $894.05 |
| 71250 | <1% | 16 | $783.78 | |
| J3490 | Unclassified drugs | <1% | 345 | $770.61 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 15 | $737.46 |
| 85610 | <1% | 173 | $599.93 | |
| 84703 | <1% | 82 | $542.88 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 16 | $542.01 |
| 81000 | <1% | 143 | $446.35 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 124 | $424.97 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 30 | $368.97 |
| 87430 | <1% | 16 | $185.64 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 50 | $167.76 |
| 85027 | <1% | 28 | $161.32 | |
| 83735 | <1% | 29 | $137.70 | |
| 83605 | <1% | 15 | $114.93 | |
| 87088 | <1% | 12 | $101.52 | |
| 87081 | <1% | 15 | $93.34 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 198 | $74.32 |
| A4217 | Sterile water/saline, 500 ml | <1% | 16 | $57.45 |
| 81003 | <1% | 14 | $19.60 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.